Table 1.
Table 1a Domain specificity of the human PA-specific monoclonal antibodies reported in this study. Table 1b Domain specificity of the human PA-specific monoclonal antibodies reported in this study.
| Table 1a | |||||
|---|---|---|---|---|---|
| Clone | VHa | VH CDR3b | Nc | Domain Specificity | |
| Donor 1 | 25G9 | VH1-18 | DIGTIFGVVIDFFDY | 1 | PA20 |
| 45F12 | VH1-2 | SGRPVEY | 1 | PA20 | |
| 47H5 | VH3-11 | DLDVGGYSSSAY | 1 | D4 | |
| 14E2 | VH3-15 | DGPMMQVLTDPRRSDYSYYTLDV | 1 | PA63 | |
| 28B1 | VH3-30 | DRIIVPGRDDYQYYGMDV | 3 | PA20 | |
| 5G4 | VH3-30 | NRVIIPRMAVPGPAAFDL | 1 | PA20 | |
| 51A10 | VH3-30 | PRAVFGVVIGYYFDF | 1 | D4 | |
| 16B9 | VH3-33 | DRVIVPADTSLSGDAFDL | 1 | PA20 | |
| 21F1 | VH3-33 | ERVIIPRTAVAGQAAFDI | 2 | PA20 | |
| 39C2 | VH3-33 | EGVIVPAGSYHYYYYMDV | 1 | PA20 | |
| 48C5 | VH4-39 | HDGKVQGVIFPGGQHMDV | 1 | PA20 | |
| Donor 2 | 3F11 | VH3-30 | ARVIVPAGSNYNQYGMDV | 1 | PA20 |
| Donor 3 | 41C2 | VH1-2 | RGAPVDY | 1 | PA20 |
| 41F6 | VH3-15 | EILGG | 1 | PA20 | |
| 16A1 | VH3-21 | EKDYYDGRGYSSWFDP | 1 | N.D. | |
| 40E10 | VH3-23 | DPESFLESLPTYYFDY | 1 | PA20 | |
| 50A4 | VH3-23 | GPGPPNQSRRVTMIVLPPPRWFDP | 1 | PA63 | |
| 55E3 | VH3-30 | DPYGADEGYYGMDV | 1 | PA20 | |
| 33G8 | VH3-30 | DRIIVPNPYSYYGLDV | 1 | PA20 | |
| 19F9 | VH3-30 | DRVIIPGTMLYYYYGMDV | 2 | PA20 | |
| 34D3 | VH3-33 | DSVIVPAVTSPRGFGMDV | 2 | PA20 | |
| 13D12 | VH3-33 | SSGSYQQPIEY | 1 | PA20 | |
| 6G2 | VH3-33 | VDGSYHQNADY | 2 | PA20 | |
| 24A10 | VH3-48 | ESGLYCGGECYSPSFDP | 2 | N.D. | |
| 29G6 | VH3-74 | GYRFGWDV | 1 | N.D. | |
| 47F9 | VH3-9 | DVGAYYYDSSGYRSAFDI | 1 | PA20 | |
| 13C10 | VH4-31 | GVGSGYYYGARNAFDI | 1 | PA20 | |
| 39B8 | VH5-51 | LGLRAIIPFDS | 1 | PA20 | |
| Table 1b | |||||
|---|---|---|---|---|---|
| Clone | VHa | VH CDR3b | Nc | Domain Specificity | |
| Donor 4 | 18C12 | VH1-2 | LAAVAGDY | 1 | PA20 |
| 33F3 | VH1-2 | TEDIVLGVAAKPHAHFDY | 1 | PA63 | |
| 24C7 | VH3-21 | LDGGDYAFDN | 1 | PA20 | |
| 59G4 | VH3-30 | ARVIVPAGSNYNQYGMDV | 1 | PA20 | |
| 3G9 | VH3-30 | DRVIVPAANRNYYYYGMDV | 6 | PA20 | |
| 2B8 | VH3-30 | DRVIVPGAHGYAYYGVDV | 4 | PA20 | |
| 1F6 | VH3-30 | EPAIVPARNSQHFFGMDV | 4 | PA20 | |
| 13C7 | VH3-30 | ERWTGILDY | 1 | PA63 | |
| 7E9 | VH3-74 | VEDIEMAELDY | 1 | PA20 | |
| 24B1 | VH3-9 | DMYGGGGYFFAK | 1 | PA63 | |
| 32C5 | VH4-34 | VTSAIAVTSTRWYIDL | 1 | PA63 | |
| 66D10 | VH4-39 | DNGGHLTFVVVDS | 1 | PA20 | |
| 32E12 | VH4-4 | DKDYFISGSYYNWFDP | 1 | PA63 | |
| Donor 5 | 11A11 | VH1-18 | DRGSRWFGEFPDEYYFDY | 1 | PA20 |
| 4A12 | VH1-46 | VNWAYGDYDFDY | 1 | D4 | |
| 40D10 | VH3-15 | DVLGIVIIVGAAH | 12 | PA20 | |
| 11F12 | VH3-23 | VVGADLRFDY | 1 | D4 | |
| 17D2 | VH3-30 | WDYVWESYRGKAFDI | 1 | PA63 | |
| 65A3 | VH3-30 | LISYDGNTKYYADSVKG | 1 | PA20 | |
| 47F12 | VH3-30 | ARVIVPAGSNYNQYGMDV | 1 | PA20 | |
| 8H2 | VH3-33 | WGYYYGSGSPPEY | 1 | PA20 | |
| 41F12 | VH3-33 | EDGSYHQGPFDY | 1 | PA20 | |
| 20C7 | VH3-43 | GPNRRDSFGLHYYGLDV | 1 | D4 | |
| 24G4 | VH3-53 | APQYDLWTGPLYGMDV | 1 | PA63 | |
| 51C5 | VH3-74 | EGRPMGLGTSVGMN | 1 | PA20 | |
| 1A5 | VH4-59 | GDMVTGDPGDY | 4 | PA63 | |
| 2E10 | VH5-51 | QSSNWEDYFQH | 1 | PA63 | |
| Donor 6 | 2E7 | VH3-23 | DQNYIDYAPSRRGSHYFYALDV | 1 | PA20 |
| Donor 7 | 18G7 | VH3-21 | EGEHSGSGSRYGMDV | 1 | N.D. |
| 8C11 | VH3-30 | EGVIVPAASNKKNYYFDL | 2 | PA20 | |
| 35F4 | VH3-30 | DRVIIPRTSAYYYYGMDV | 22 | PA20 | |
| 32A11 | VH3-30 | ERLTGILDY | 1 | PA63 | |
| 17A9 | VH3-30 | GGGSGSSDY | 1 | PA63 | |
| 29G3 | VH3-30 | ADYAGGRRFDL | 1 | PA63 | |
| 28E3 | VH3-49 | ADYNNRNYASDV | 4 | PA20 | |
| 40E2 | VH4-59 | HGKYGGFSSGWFDP | 1 | N.D. | |
Germline H chain variable region gene used by the individual monoclonal antibodies.
Heavy chain CDR3 region used to define independent B-cell rearrangements (families).
Number of sequence unique, somatically-derived members of each rearrangement (family) isolated.
Domain specificity of individual antibodies. Specificity was list as N.D. if no conclusive assignment could be made (see text). Listing continued in Table 1b.
Germline H chain variable region gene used by the individual monoclonal antibodies.
Heavy chain CDR3 region used to define independent B-cell rearrangements (families).
Number of sequence unique, somatically-derived members of each rearrangement (family) isolated.
Domain specificity of individual antibodies. Specificity was list as N.D. if no conclusive assignment could be made (see text).